trending Market Intelligence /marketintelligence/en/news-insights/trending/AVMO40DbewApnoLZHVRuEw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Melinta Therapeutics to list on Nasdaq in reverse merger transaction

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Melinta Therapeutics to list on Nasdaq in reverse merger transaction

Privately held Melinta Therapeutics is acquiring Cempra Inc. in a reverse merger to list on Nasdaq.

The resulting company will adopt the Melinta Therapeutics name and will be 48% owned by former Cempra shareholders.

The new company's board will comprise nine members: four nominated by Cempra and five, including the chairman, to be nominated by Melinta.

Both the companies will work through a joint selection committee to appoint a CEO.

The transaction is backed by the board of both companies and is expected to close during the fourth quarter of 2017.

The new company will focus on the commercial launch of Melinta's Baxdela, which is approved in the U.S. for acute bacterial skin and skin structure infections. Baxdela is also being evaluated as a treatment of community-acquired bacterial pneumonia and complicated urinary tract infections.

Cempra has an ongoing ophthalmic development program for solithromycin and is completing preclinical work to support a potential investigational new drug application in 2018.

Morgan Stanley, Stifel, and Skadden and Wyrick Robbins advised Cempra on the deal. Melinta was advised by J.P. Morgan Securities LLC and Willkie Farr & Gallagher LLP.

Malin Corp. PLC is an investor in Melinta Therapeutics.